Latest Articles

A diverse array of biological medicines are now used to prevent and treat a wide range of illnesses. This article will discuss the development of cell lines in biopharma and will touch on key considerations, such as future manufacturability.

Antimicrobial resistance (AMR) is threatening the effective treatment and prevention of a wide range of infections, with serious potential consequences for health and the economy. We spoke to Dr. Alaa Riezk, research associate at the Centre for Antimicrobial Optimisation (CAMO), Imperial College London, about the problem of usage and dosage of antimicrobials and AMR and how he and the team are working to address it.

Martin Farley, sustainable research adviser at UCL and director of Green Lab Associates, was invited to Technology Networks’ Ask Me Anything session to answer your questions about the future of sustainability in research and laboratory practices.

In this opinion piece, Neil Ward explores how advances in sequencing could help to provide new insights for rare disease patients.

Spider silk is a remarkable material, offering high tensile strength and natural elasticity. In this article, learn how a group of scientists are currently exploring its untapped potential in medical and materials science.

This article focuses on the use of high-throughput screening approaches in drug discovery and discusses the latest developments in this area.

Insight into the history of human–pathogen interactions, how different societies responded to disease and the origin of pathogens supports our understanding of human health and evolution. We explore what we're still learning about ancient pathogens and diseases.

This article explores the importance of early risk prediction in preventing cardiovascular disease (CVD), the role of biomarkers in this prediction and nutritional habits to reduce the risk of CVD.

Leukaemia UK recently announced that it will channel £600,000 into four new AML research projects. Technology Networks spoke to Kate Nash, research communications manager at Leukaemia UK, to learn more about the innovative research projects aiming to improve the treatment of AML.

Drew Burch discusses how next-gen mRNA technology is one of the most valuable tools to combat and control disease outbreaks and why continued investment in this field is crucial for maintaining our pandemic preparedness.